A GLP-1 analogue of formula I or a pharmaceutically acceptable salt or composition thereof: Xaa7 is L-His, D-histidine, deamino-histidine, 2-aminohistidine, β-hydroxy-histidine, homohistidine, α-fluoromethyl-histidine , or α-methyl-histidine； wherein: Q is linker II, III or IV: ** Formula ** wherein: R1 is hydrogen, (C1-C6) alkyl, or (C1-C6) alkoxy, R2 is hydrogen, (C1) alkyl -C6), or (C1-C6) alkoxy, R3 is hydrogen, (C1-C6) alkyl or forms a 5-8 membered ring with R1 or R2, X is hydrogen, fluorine, hydroxy, trifluoromethyl, or oxygen , Y is hydrogen, hydroxyl, fluorine, or (C1-C6) alkyl, Z is nitrogen, carbon, oxygen, or sulfur, W does not exist when Z is nitrogen, oxygen, or sulfur； W is hydrogen or fluorine when Z is carbon； Xaa14 is serine, or histidine； and one or more carbon atoms of Xaa14 are optionally substituted with one or more alkyl groups； Xaa16 is valine, lysine or leucine； and one or more carbon atoms of Xaa16 are optionally substituted with one or more alkyl groups； or Xaa16 is lysine bound with TU, where, T is γ-glutamic acid, β-alanine, γ-aminobutyric acid, HOOC (CH2) nCOOH, or ** Formula ** where n is 1, 2, 3, 4 , 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27； k is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10； U exists and is a fatty acid with a length of 8 to 20 carbons only when T is γ-glutamic acid, β-alanine, γ-aminobutyric acid or ** Formula ** where k is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10； Xaa18 is serine, arginine, or lysine； and one or more of the Xaa18 carbon atoms are optionally substituted with one or more alkyl groups.Un análogo de GLP-1 de fórmula I o una sal o composición farmacéuticamente aceptable del mismo: Xaa7 es L-His, D-histidina, desamino-histidina, 2-aminohistidina, &beta；-hidroxi-histidina, homohistidina, &alpha；- fluorometil-histidina, o &alpha；-metil-histidina； en donde: Q es el enlazador II, III o IV:**Fórmula** e
